AKT1 and cholangiocarcinoma: As revealed from the KEGG pathway analysis, YCHD produced therapeutic effects on cholangiocarcinoma by regulating pathways (e.g., hepatitis B, the MAPK signaling pathway, the PI3K-Akt signaling pathway, and MicroRNAs in cancer).